Big data specialists could breathe life into the pharma sector
Increased hiring of big data experts and data scientists could help to revitalise the pharmaceutical sector, according to NonStop Recruitment.
An analysis by the pharmaceutical recruitment specialists found that a greater focus on exploiting data could drive greater efficiency which would benefit the entire sector. The price of developing new drugs has risen to prohibitive levels with the failure of late stage clinical trials often costing firms millions. NonStop has argued that hiring big data specialists could mean that the data from these trials is more effectively exploited.
Abid Kanji, Associate Director of NonStop Recruitment, comments: “As we all know, the process of getting a new drug to market is a long and costly one. Firms produce enormous amounts of data from trials and testing, but currently use it very inefficiently. Taking on larger numbers of data scientists and big data experts could mean that organisations can exploit the data more effectively and then save costs further down the line when it comes to drug development. This isn’t reinventing the wheel. It’s a relatively simple solution to an obvious problem that is causing massive wastage. The data can be used to help direct research more efficiently and could reduce the amount of time that firms spend pursuing unviable opportunities. The process would start with sharing information internally, but eventually the entire sector could reap the benefits.”
“The pharmaceutical industry arrived somewhat late to the ‘big data revolution’ and with the sector in such a tumultuous state it seems clear that firms should be doing all they can to become more efficient. They don’t even need to take on an expert with extensive direct experience in the pharmaceutical sector, firms simply require specialists who understand how to break down and analyse data to spot areas where their employers could improve efficiency. This could be a significant opportunity for the entire industry and it’s one that we hope they will adopt.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance